Compare Abbott Laboratories (ABT) vs T Rowe Price Group Inc (TROW) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs T Rowe Price Group Inc — how do they compare? Abbott Laboratories trades at $95.13 (market cap $166.94B), while T Rowe Price Group Inc trades at $117.02 (market cap $25.75B). The key difference: Abbott Laboratories is far larger — about 6.5× T Rowe Price Group Inc's market cap, and T Rowe Price Group Inc pays the higher dividend (4.33%). Which is the better fit depends on your goals.
| ABT | TROW | |
|---|---|---|
Market Cap | $166.94B | $25.75B |
Sector | Health | Financials |
52-Week High | $136.62 | $120.16 |
52-Week Low | $82.57 | $86.19 |
Enterprise Value | $193.69B | $22.45B |
Dividend Yield | 2.63% | 4.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
T. Rowe Price (TROW) trades at $120.16, up 1.36% with bullish technical indicators showing strong momentum above key support levels. The company maintains solid fundamentals with $7.31B revenue, 28.28% net margin, and attractive valuation at 12.78 P/E. Recent earnings beat expectations in Q1 2026, while strategic initiatives in institutional services and AI-focused content demonstrate proactive positioning.
TROW presents a mixed outlook with strong profitability and cash flow generation offset by analyst caution. The stock trades above consensus target ($101.57) but offers dividend appeal with recent $1.30 payout. Key risks include equity outflows and market sensitivity, while institutional enhancements and debt-free balance sheet provide stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About T Rowe Price Group Inc
T. Rowe Price provides asset-management services for individual and institutional investors. It offers a broad range of no-load U.S. and international stock, hybrid, bond, and money market funds. At the end of August 2022, the firm had $1.339 trillion in managed assets, composed of equity (54%), balanced (30%), fixed-income (13%), and alternatives (3%) offerings. Approximately two thirds of the company's managed assets are held in retirement-based accounts, which provides T. Rowe Price with a somewhat stickier client base than most of its peers. The firm also manages private accounts, provides retirement planning advice, and offers discount brokerage and trust services. The company is primarily a U.S.-based asset manager, deriving just under 10% of its AUM from overseas.
Read more on TROW →
